IN2012DN03032A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03032A
IN2012DN03032A IN3032DEN2012A IN2012DN03032A IN 2012DN03032 A IN2012DN03032 A IN 2012DN03032A IN 3032DEN2012 A IN3032DEN2012 A IN 3032DEN2012A IN 2012DN03032 A IN2012DN03032 A IN 2012DN03032A
Authority
IN
India
Prior art keywords
receptor antagonist
arb
salts
manufacture
processes
Prior art date
Application number
Inventor
Gottfried Sedelmeier
Florian Andreas Rampf
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41716392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN03032A publication Critical patent/IN2012DN03032A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/32—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/32—Separation; Purification; Stabilisation; Use of additives
    • C07C253/34—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to processes for the manufacture of an angiotensin receptor blocker (ARB; also called angiotension II receptor antagonist or AT1 receptor antagonist) and salts thereof, to novel intermediates and process steps.
IN3032DEN2012 2009-10-27 2010-10-25 IN2012DN03032A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174264A EP2316821A1 (en) 2009-10-27 2009-10-27 Process for the manufacture of organic compounds
PCT/EP2010/066041 WO2011051213A1 (en) 2009-10-27 2010-10-25 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
IN2012DN03032A true IN2012DN03032A (en) 2015-07-31

Family

ID=41716392

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3032DEN2012 IN2012DN03032A (en) 2009-10-27 2010-10-25

Country Status (23)

Country Link
US (1) US20120238761A1 (en)
EP (2) EP2316821A1 (en)
JP (1) JP2013508436A (en)
KR (1) KR20120098652A (en)
CN (1) CN102596899A (en)
AR (1) AR079104A1 (en)
AU (1) AU2010311636B2 (en)
BR (1) BR112012009815A2 (en)
CA (1) CA2777031A1 (en)
CL (1) CL2012001081A1 (en)
CO (1) CO6531487A2 (en)
EC (1) ECSP12011833A (en)
IL (1) IL219111A0 (en)
IN (1) IN2012DN03032A (en)
MA (1) MA33692B1 (en)
MX (1) MX2012005025A (en)
NZ (1) NZ599218A (en)
PE (1) PE20121501A1 (en)
RU (1) RU2012121591A (en)
TN (1) TN2012000154A1 (en)
TW (1) TW201124389A (en)
WO (1) WO2011051213A1 (en)
ZA (1) ZA201202490B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321038B (en) * 2011-07-11 2014-03-26 安徽省虹升生物科技有限公司 Improved valsartan preparation method
FR2981077B1 (en) * 2011-10-11 2013-11-01 Michelin Soc Tech METHOD FOR PREPARING A MASTER MIXTURE OF DIENE ELASTOMER AND SILICA
US10745363B2 (en) 2016-09-02 2020-08-18 Nanjing Noratech Pharmaceuticals Co., Ltd Crystal forms of valsartan disodium salt
CN110078640B (en) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 Synthesis method of valsartan intermediate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874867A (en) 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
DK0443983T3 (en) 1990-02-19 1996-03-18 Ciba Geigy Ag acrylic Compounds
JPH04297466A (en) 1990-06-22 1992-10-21 Nippon Shinyaku Co Ltd Tetrazole derivative and medicine
GB9222700D0 (en) * 1992-10-29 1992-12-09 Smithkline Beecham Plc Chemical compounds
GB0222056D0 (en) 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
ITMI20032267A1 (en) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph PROCDIMENTO FOR PREPARATION OF VALSARTAN AND ITS INTERMEDIATES
HRP20030965A2 (en) * 2003-11-24 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of (s)-n-pentanoyl-n-[[2'-(
EP1714963A1 (en) * 2005-04-19 2006-10-25 IPCA Laboratories Limited Process for the Preparation of Valsartan and its Intermediates
CA2619955A1 (en) * 2005-08-22 2007-03-22 Alembic Limited Process for preparing valsartan
WO2008004110A2 (en) * 2006-07-03 2008-01-10 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
CN101450917B (en) * 2007-12-06 2012-07-11 浙江海正药业股份有限公司 Valsartan synthesis method
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan

Also Published As

Publication number Publication date
EP2493848A1 (en) 2012-09-05
CA2777031A1 (en) 2011-05-05
CO6531487A2 (en) 2012-09-28
TW201124389A (en) 2011-07-16
IL219111A0 (en) 2012-06-28
KR20120098652A (en) 2012-09-05
NZ599218A (en) 2014-02-28
EP2316821A1 (en) 2011-05-04
AR079104A1 (en) 2011-12-28
AU2010311636B2 (en) 2014-03-06
CN102596899A (en) 2012-07-18
TN2012000154A1 (en) 2013-12-12
MA33692B1 (en) 2012-10-01
PE20121501A1 (en) 2012-11-15
AU2010311636A1 (en) 2012-05-03
ZA201202490B (en) 2012-12-27
BR112012009815A2 (en) 2016-10-18
JP2013508436A (en) 2013-03-07
ECSP12011833A (en) 2012-06-29
US20120238761A1 (en) 2012-09-20
RU2012121591A (en) 2013-12-10
WO2011051213A1 (en) 2011-05-05
CL2012001081A1 (en) 2013-06-14
MX2012005025A (en) 2012-06-08

Similar Documents

Publication Publication Date Title
TN2011000673A1 (en) Bace inhibitors
WO2010070658A3 (en) Improved process for the preparation of endothelin receptor antagonists
PT2470546E (en) Hexahydrooxazinopteridine compounds for use as mtor inhibitors
UA115136C2 (en) Substituted 4-phenyl-pyridines for the treatment of nk-1 receptor related diseases
IN2012DN02642A (en)
WO2011022596A3 (en) Preparation of bazedoxifene and its salts
EP2540796A4 (en) ß-SIALON PHOSPHOR, USES THEREOF, PROCESS FOR PRODUCTION OF ß-SIALON PHOSPHOR
CL2009000503A1 (en) Preparation process of compounds derived from 2-amino-5-cyanobenzoic acid-3-substituted or 1h-pyrazole-5-carboxamide.
JO2887B1 (en) Spiropiperidine compounds as orl-1 receptor antagonists‎
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
MX2010009003A (en) Cyclohexanedimethanamine by direct amination of cyclohexanedimethanol.
UA105785C2 (en) Process for purifying lipopeptides
BR112012009823A2 (en) water dispersible polyurethane
GEP20135903B (en) Method of (1s, 2r)-milnacipran synthesis
EA201270280A1 (en) Pyrimidine Compounds as Inhibitors in the Treatment of Tuberculosis
MX2010000724A (en) Method for reducing intracranial pressure.
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
UA106619C2 (en) A process for producing 1- (2-halogen biphenyl-4-yl) cyclopropanecarboxylic acid
IN2012DN03032A (en)
UA106386C2 (en) Method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid
IN2012DN01929A (en)
MX2012010443A (en) Process for the preparation of 5-substituted 1-alkyltetrazoles.
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
IN2014DN10209A (en)
UA110626C2 (en) Process for preparing pan-cdk inhibitors of the formula (i), and also to intermediates in the preparation